None

First comprehensive analysis reveals long-term effectiveness of SERMs for preventing breast cancer

Selective oestrogen receptor modulators (SERMs: tamoxifen, raloxifene, arzoxifene, and lasofoxifene) significantly reduce the risk of developing the most common type of breast cancer among women at bo...

[Comment] Breast cancer prevention: SERMs come of age

In The Lancet, Jack Cuzick and colleagues present an overview of nine trials of selective oestrogen receptor modulators (SERMs) for breast cancer prevention, the results of more than a quarter of a ce...

Lancet review supports breast cancer chemoprevention

Selective oestrogen receptor modulators (SERMs), such as tamoxifen and raloxifene, reduce the incidence of breast cancer during treatment and for at least five years after treatment, according to an...

Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.

Arzoxifene increased bone mineral density and decreased bone turnover to a significantly greater extent than raloxifene. The hot flush incidence was lower with arzoxifene than raloxifene. INTRODUCTION...

Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.

BACKGROUND: Arzoxifene is a selective estrogen receptor modulator (SERM) more potent in preclinical testing than currently available agents. Its effects on clinical outcomes are not known. METHODS: In...

Third generation selective estrogen receptor modulators benefits beyond bone: effects on breast.

The selective estrogen receptor modulators (SERMs) are substances with estrogenic/anti-estrogen effect that act differently depending on the tissue and composition. Since the discovery that tamoxifen...

Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action.

The selective estrogen receptor modulators (SERMs) are substances with estrogenic/anti-estrogen effect that act differently depending on the tissue and composition. Since the discovery that tamoxifen...